J&J, Vor ally to assess bispecific and stem cell therapy in AML

J&J, Vor ally to assess bispecific and stem cell therapy in AML

Source: 
Fierce Biotech
snippet: 

Johnson & Johnson has teamed up with Vor Biopharma to study one of its bispecific antibodies in combination with technology designed to improve tolerability.

Vor, which was founded by Siddhartha Mukherjee, is built on a way to make healthy cells invisible to targeted treatments. The process entails taking stem cells from a healthy matched donor, deleting the gene that encodes for the target of the therapy and giving the engineered cells to the patient. When the engineered cells engraft into bone marrow, the patient will make blood cells that lack the surface receptor targeted by the therapy, thereby preventing on-target toxicity.